Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis

NCT06906497 is registered in ClinicalTrials.gov with Johann E Gudjonsson MD PhD as lead sponsor.

NCT NCT06906497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Lead sponsor
Johann E Gudjonsson MD PhD
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 2, 2025
Completion date
July 31, 2028
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis